Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

NCT04983745 is registered in ClinicalTrials.gov with West Cancer Center as lead sponsor.

NCT NCT04983745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer
Lead sponsor
West Cancer Center
Phase
Phase 2
Overall status
Unknown status
Start date
November 29, 2021
Completion date
August 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

homologous recombination deficient solid tumors